Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Syros Pharmaceuticals, Inc. (SYRS) since 2016 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Syros Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1556263.
Total stock buying since 2016: $52,153,133.
Total stock sales since 2016: $8,789,379.
Total stock option exercises since 2016: $635,422.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 200,000 | $321,867 | 549,873 | $174,725 | 255,939 | $0 |
| 2023 | 904,977 | $3,999,998 | 20,611 | $87,388 | 99,373 | $0 |
| 2022 | 16,932 | $105,951 | 2,208 | $7,655 | 0 | $0 |
| 2021 | 0 | $0 | 11,128 | $128,458 | 3,628 | $3,664 |
| 2020 | 10,000 | $88,590 | 403,493 | $4,722,855 | 45,667 | $231,697 |
| 2019 | 553,332 | $4,099,586 | 420,086 | $3,182,670 | 52,401 | $159,299 |
| 2018 | 209,424 | $1,999,999 | 0 | $0 | 110,588 | $223,940 |
| 2017 | 124,774 | $1,127,817 | 22,114 | $485,628 | 15,550 | $16,822 |
| 2016 | 3,232,746 | $40,409,325 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-12 | 0 | $0 | 37,070 | $10,008 | 0 | $0 |
| 2024-11 | 0 | $0 | 502,202 | $112,238 | 0 | $0 |
| 2024-10 | 0 | $0 | 0 | $0 | 111,875 | $0 |
| 2024-09 | 200,000 | $321,867 | 0 | $0 | 10,000 | $0 |
| 2024-06 | 0 | $0 | 0 | $0 | 8,000 | $0 |
| 2024-04 | 0 | $0 | 10,601 | $52,479 | 0 | $0 |
| 2024-03 | 0 | $0 | 0 | $0 | 126,064 | $0 |
| 2023-12 | 904,977 | $3,999,998 | 12,574 | $55,953 | 0 | $0 |
| 2023-10 | 0 | $0 | 0 | $0 | 75,375 | $0 |
| 2023-09 | 0 | $0 | 0 | $0 | 7,998 | $0 |
| 2023-07 | 0 | $0 | 8,037 | $31,435 | 0 | $0 |
| 2023-03 | 0 | $0 | 0 | $0 | 16,000 | $0 |
| 2022-09 | 16,932 | $105,951 | 0 | $0 | 0 | $0 |
| 2022-01 | 0 | $0 | 2,208 | $7,655 | 0 | $0 |
| 2021-03 | 0 | $0 | 3,628 | $34,371 | 3,628 | $3,664 |
| 2021-02 | 0 | $0 | 7,500 | $94,087 | 0 | $0 |
| 2020-12 | 0 | $0 | 0 | $0 | 29,917 | $215,791 |
| 2020-11 | 0 | $0 | 5,990 | $52,557 | 0 | $0 |
| 2020-10 | 0 | $0 | 5,990 | $52,411 | 0 | $0 |
| 2020-09 | 0 | $0 | 5,990 | $62,236 | 0 | $0 |
| 2020-08 | 0 | $0 | 181,067 | $2,366,638 | 15,750 | $15,906 |
| 2020-07 | 0 | $0 | 12,370 | $142,485 | 0 | $0 |
| 2020-06 | 0 | $0 | 160,690 | $1,770,965 | 0 | $0 |
| 2020-05 | 10,000 | $88,590 | 5,990 | $55,239 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-12-02 | Simonian Nancy A | Sale | 37,070 | .27 | 10,008 |
| 2024-11-25 | Simonian Nancy A | Sale | 134,713 | .27 | 35,698 |
| 2024-11-19 | Quirk Gerald E (Chief Legal & Compliance Offic) | Sale | 46,657 | .22 | 10,311 |
| 2024-11-18 | Haas Jason (Chief Financial Officer) | Sale | 137,803 | .21 | 28,938 |
| 2024-11-18 | Chee Conley (President & CEO) | Sale | 134,797 | .20 | 26,959 |
| 2024-11-18 | Stephens Kristin (Chief Development Officer) | Sale | 36,133 | .22 | 7,949 |
| 2024-11-18 | Roth David (Chief Medical Officer) | Sale | 12,099 | .20 | 2,383 |
| 2024-10-31 | Haas Jason (Chief Financial Officer) | Option Ex | 18,875 | .00 | 0 |
| 2024-10-31 | Chee Conley (President & CEO) | Option Ex | 17,000 | .00 | 0 |
| 2024-10-31 | Stephens Kristin (Chief Development Officer) | Option Ex | 17,000 | .00 | 0 |
| 2024-10-31 | Roth David (Chief Medical Officer) | Option Ex | 18,875 | .00 | 0 |
| 2024-10-31 | Simonian Nancy A | Option Ex | 40,125 | .00 | 0 |
| 2024-09-30 | Quirk Gerald E (Chief Legal & Compliance Offic) | Option Ex | 10,000 | .00 | 0 |
| 2024-09-12 | Haas Jason (Chief Financial Officer) | Buy | 45,344 | 1.68 | 75,996 |
| 2024-09-11 | Haas Jason (Chief Financial Officer) | Buy | 19,293 | 1.58 | 30,444 |
| 2024-09-11 | Chee Conley (President & CEO) | Buy | 50,000 | 1.71 | 85,400 |
| 2024-09-10 | Haas Jason (Chief Financial Officer) | Buy | 35,363 | 1.55 | 54,777 |
| 2024-09-10 | Chee Conley (President & CEO) | Buy | 50,000 | 1.50 | 75,250 |
| 2024-06-01 | Dunsire Deborah | Option Ex | 4,000 | .00 | 0 |
| 2024-06-01 | Akkaraju Srinivas | Option Ex | 4,000 | .00 | 0 |
| 2024-04-03 | Roth David (Chief Medical Officer) | Sale | 10,451 | 4.95 | 51,732 |
| 2024-04-02 | Roth David (Chief Medical Officer) | Sale | 150 | 4.98 | 747 |
| 2024-03-31 | Haas Jason (Chief Financial Officer) | Option Ex | 15,333 | .00 | 0 |
| 2024-03-31 | Chee Conley (President & CEO) | Option Ex | 13,666 | .00 | 0 |
| 2024-03-31 | Stephens Kristin (Chief Development Officer) | Option Ex | 13,666 | .00 | 0 |
| 2024-03-31 | Roth David (Chief Medical Officer) | Option Ex | 15,333 | .00 | 0 |
| 2024-03-31 | Simonian Nancy A | Option Ex | 45,566 | .00 | 0 |
| 2024-03-27 | Quirk Gerald E (Chief Legal & Compliance Offic) | Option Ex | 22,500 | .00 | 0 |
| 2023-12-21 | Akkaraju Srinivas (Director) | Buy | 904,977 | 4.42 | 3,999,998 |
| 2023-12-12 | Roth David (Chief Medical Officer) | Sale | 6,287 | 4.95 | 31,120 |
| 2023-12-06 | Roth David (Chief Medical Officer) | Sale | 6,287 | 3.95 | 24,833 |
| 2023-10-31 | Chee Conley (Chief Commercial Officer) | Option Ex | 17,000 | .00 | 0 |
| 2023-10-31 | Stephens Kristin (Chief Development Officer) | Option Ex | 17,000 | .00 | 0 |
| 2023-10-31 | Roth David (Chief Medical Officer) | Option Ex | 18,875 | .00 | 0 |
| 2023-10-11 | Quirk Gerald E (Chief Legal & Compliance Offic) | Option Ex | 22,500 | .00 | 0 |
| 2023-09-16 | Alles Mark J (Director) | Option Ex | 2,666 | .00 | 0 |
| 2023-09-16 | Young Richard A (Director) | Option Ex | 2,666 | .00 | 0 |
| 2023-09-16 | Akkaraju Srinivas (Director) | Option Ex | 2,666 | .00 | 0 |
| 2023-07-31 | Roth David (Chief Medical Officer) | Sale | 7,348 | 3.95 | 29,024 |
| 2023-07-17 | Olson Eric R (Chief Scientific Officer) | Sale | 689 | 3.50 | 2,411 |
| 2023-03-31 | Haas Jason (Chief Financial Officer) | Option Ex | 2,000 | .00 | 0 |
| 2023-03-31 | Chee Conley (Chief Commercial Officer) | Option Ex | 2,000 | .00 | 0 |
| 2023-03-31 | Stephens Kristin (Chief Development Officer) | Option Ex | 2,000 | .00 | 0 |
| 2023-03-31 | Olson Eric R (Chief Scientific Officer) | Option Ex | 2,000 | .00 | 0 |
| 2023-03-31 | Roth David (Chief Medical Officer) | Option Ex | 2,000 | .00 | 0 |
| 2023-03-31 | Simonian Nancy A (President & CEO) | Option Ex | 6,000 | .00 | 0 |
| 2022-09-30 | Tyson Timothy (Director) | Buy | 14,000 | 6.37 | 89,180 |
| 2022-09-29 | Tyson Timothy (Director) | Buy | 2,932 | 5.72 | 16,771 |
| 2022-01-05 | Olson Eric R (Chief Scientific Officer) | Sale | 2,208 | 3.47 | 7,655 |
| 2021-03-15 | Olson Eric R (Chief Scientific Officer) | Sale | 3,628 | 9.47 | 34,371 |
| 2021-03-15 | Olson Eric R (Chief Scientific Officer) | Option Ex | 3,628 | 1.01 | 3,664 |
| 2021-02-16 | Young Richard A (Director) | Sale | 3,750 | 12.05 | 45,187 |
| 2021-02-08 | Young Richard A (Director) | Sale | 3,750 | 13.04 | 48,900 |
| 2020-12-18 | Simonian Nancy A (President & CEO) | Option Ex | 29,917 | 7.21 | 215,791 |
| 2020-11-17 | Young Richard A (Director) | Sale | 5,357 | 8.75 | 46,873 |
| 2020-11-16 | Young Richard A (Director) | Sale | 633 | 8.98 | 5,684 |
| 2020-10-19 | Young Richard A (Director) | Sale | 5,673 | 8.75 | 49,638 |
| 2020-10-15 | Young Richard A (Director) | Sale | 317 | 8.75 | 2,773 |
| 2020-09-15 | Young Richard A (Director) | Sale | 5,990 | 10.39 | 62,236 |
| 2020-08-18 | Olson Eric R (Chief Scientific Officer) | Sale | 10,787 | 13.00 | 140,231 |
| 2020-08-18 | Olson Eric R (Chief Scientific Officer) | Option Ex | 10,787 | 1.01 | 10,894 |
| 2020-08-18 | Akkaraju Srinivas (Director) | Sale | 158,583 | 13.10 | 2,076,802 |
| 2020-08-17 | Olson Eric R (Chief Scientific Officer) | Sale | 4,963 | 13.00 | 64,519 |
| 2020-08-17 | Olson Eric R (Chief Scientific Officer) | Option Ex | 4,963 | 1.01 | 5,012 |
| 2020-08-17 | Young Richard A (Director) | Sale | 5,990 | 12.59 | 75,414 |
| 2020-08-17 | Akkaraju Srinivas (Director) | Sale | 744 | 13.00 | 9,672 |
| 2020-07-15 | Young Richard A (Director) | Sale | 5,990 | 11.85 | 70,981 |
| 2020-07-07 | Olson Eric R (Chief Scientific Officer) | Sale | 1,753 | 11.72 | 20,538 |
| 2020-07-01 | Akkaraju Srinivas (Director) | Sale | 4,627 | 11.02 | 50,966 |
| 2020-06-25 | Akkaraju Srinivas (Director) | Sale | 54,972 | 11.15 | 612,827 |
| 2020-06-24 | Akkaraju Srinivas (Director) | Sale | 48,775 | 11.07 | 539,792 |
| 2020-06-23 | Akkaraju Srinivas (Director) | Sale | 50,953 | 11.11 | 565,934 |
| 2020-06-15 | Young Richard A (Director) | Sale | 5,990 | 8.75 | 52,412 |
| 2020-05-15 | Young Richard A (Director) | Sale | 5,990 | 9.22 | 55,239 |
| 2020-05-13 | Alles Mark J (Director) | Buy | 10,000 | 8.86 | 88,590 |
| 2020-04-15 | Young Richard A (Director) | Sale | 23,960 | 8.75 | 209,650 |
| 2020-02-18 | Olson Eric R (Chief Scientific Officer) | Sale | 1,446 | 7.38 | 10,674 |
| 2019-12-23 | Simonian Nancy A (President & CEO) | Option Ex | 52,401 | 3.04 | 159,299 |
| 2019-11-12 | Springhorn Jeremy P. (Chief Business Officer) | Buy | 10,121 | 4.97 | 50,271 |
| 2019-11-11 | Springhorn Jeremy P. (Chief Business Officer) | Buy | 9,879 | 4.99 | 49,325 |
| 2019-08-16 | Young Richard A (Director) | Sale | 22,700 | 10.00 | 227,000 |
| 2019-08-15 | Young Richard A (Director) | Sale | 2,300 | 10.00 | 23,000 |
| 2019-07-17 | Nelsen Robert (10% Owner) | Sale | 34,521 | 7.70 | 265,673 |
| 2019-07-16 | Nelsen Robert (10% Owner) | Sale | 25,779 | 7.81 | 201,282 |
| 2019-07-15 | Nelsen Robert (10% Owner) | Sale | 2,700 | 8.27 | 22,315 |
| 2019-04-09 | Akkaraju Srinivas (Director) | Buy | 533,332 | 7.50 | 3,999,990 |
| 2019-03-14 | Nelsen Robert (10% Owner) | Sale | 43,000 | 8.15 | 350,450 |
| 2019-03-13 | Nelsen Robert (10% Owner) | Sale | 84,411 | 8.04 | 678,917 |
| 2019-03-12 | Nelsen Robert (10% Owner) | Sale | 40,092 | 7.37 | 295,357 |
| 2019-03-11 | Nelsen Robert (10% Owner) | Sale | 44,878 | 6.49 | 291,347 |
| 2019-03-08 | Nelsen Robert (10% Owner) | Sale | 84,496 | 6.93 | 585,303 |
| 2019-03-07 | Nelsen Robert (10% Owner) | Sale | 35,209 | 6.87 | 242,026 |
| 2018-11-29 | Simonian Nancy A (President & CEO) | Option Ex | 110,588 | 2.02 | 223,940 |
| 2018-01-31 | Akkaraju Srinivas (Director) | Buy | 209,424 | 9.55 | 1,999,999 |
| 2017-12-15 | Springhorn Jeremy P. (Chief Business Officer) | Buy | 15,000 | 9.08 | 136,260 |
| 2017-12-14 | Akkaraju Srinivas (Director) | Buy | 26,600 | 8.99 | 239,134 |
| 2017-12-13 | Akkaraju Srinivas (Director) | Buy | 68,400 | 8.97 | 613,548 |
| 2017-12-12 | Akkaraju Srinivas (Director) | Buy | 14,774 | 9.40 | 138,875 |
| 2017-10-23 | Desimone Colleen Elizabeth (Principal Accounting Officer) | Sale | 550 | 16.06 | 8,833 |
| 2017-10-23 | Desimone Colleen Elizabeth (Principal Accounting Officer) | Option Ex | 550 | 3.04 | 1,672 |
| 2017-08-14 | Young Richard A (Director) | Sale | 3,282 | 22.00 | 72,204 |
| 2017-08-07 | Olson Eric R (Chief Scientific Officer) | Sale | 2,500 | 23.59 | 58,970 |
| 2017-08-07 | Olson Eric R (Chief Scientific Officer) | Option Ex | 2,500 | 1.01 | 2,525 |
| 2017-07-25 | Olson Eric R (Chief Scientific Officer) | Sale | 12,500 | 21.85 | 273,125 |
| 2017-07-25 | Olson Eric R (Chief Scientific Officer) | Option Ex | 12,500 | 1.01 | 12,625 |
| 2017-07-25 | Young Richard A | Sale | 3,282 | 22.09 | 72,496 |
| 2016-07-06 | Green Jeremy (10% Owner) | Buy | 432,746 | 12.50 | 5,409,325 |
| 2016-07-06 | Polaris Entrepreneurs' Fund Vii, L.p. (10% Owner) | Buy | 400,000 | 12.50 | 5,000,000 |
| 2016-07-06 | Deerfield Private Design Fund Iii, L.p. | Buy | 400,000 | 12.50 | 5,000,000 |
| 2016-07-06 | Nashat Amir (Director) | Buy | 400,000 | 12.50 | 5,000,000 |
| 2016-07-06 | Purcell Dennis J | Buy | 400,000 | 12.50 | 5,000,000 |
| 2016-07-06 | Kania Edwin M Jr (10% Owner) | Buy | 400,000 | 12.50 | 5,000,000 |
| 2016-07-06 | Bybee Clinton (10% Owner) | Buy | 400,000 | 12.50 | 5,000,000 |
| 2016-07-06 | Nelsen Robert (Director) | Buy | 400,000 | 12.50 | 5,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of SYRS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Syros Pharmaceuticals, Inc. (symbol SYRS, CIK number 1556263) see the Securities and Exchange Commission (SEC) website.